Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization of Revolution’s RAS(ON) inhibitor portfolio, particularly the clinical advancement of lead candidate RMC-6236.
The agreement includes a synthetic royalty deal and a senior secured credit facility. Revolution retains full rights to its programs, while Royalty Pharma secures a return based on future sales.
